DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.21 · Revenue $13.50M · 2 analysts
Est. EPS $-0.22 · Revenue $13.50M · 2 analysts
Est. EPS $-0.77 · Revenue $54.00M · 3 analysts
Est. EPS $-0.19 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-32.8M | -34.0% | -1.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-29.1M | -31.7% | +10.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.4% | -48.8% | +7.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 11.81x | +42.7% | -26.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $61.4M | +32.4% | -15.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.70 vs -0.68 | -2.3% | -0.19 vs -0.20 | +5.4% |
| Revenue Surprise | — | — | $0 vs $13.5M | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Pauls Dietrich John | director, officer: President & CEO | Voting Common Shares, no par value per share | A | 60,200 | — |
| Jan 2, 2026 | Parsons James T. | director | Common Stock | A | 10,095 | $8.42 |
| Jan 2, 2026 | Giuffre Randall Michael | director | Common Stock | A | 6,175 | $8.42 |
| Jan 2, 2026 | Semba Charles Pauling | director | Common Stock | A | 3,355 | $8.42 |
| Nov 25, 2025 | STAHLBERG JAN | 10 percent owner | Common Shares | A | 73,099 | $8.57 |
Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2026 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section. Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appear in the section entitled Cautionary Statements Note regarding Forward-Looking Statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and most recent quarterly report on Form 10-Q. DiaMedica's SEC filings are available at www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, August 11, 2026, and may no longer be accurate at the time of any replay or transcript reading. Following management's remarks, we will open the phone lines for questions. I would now like to introduce your host for today's call, Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin. Dietrich Pauls: Thank you, Morgan, and thank you all for joining us today. With me this morning are Dr. Julie Krop, our Chief Medical Officer; and Scott Kellen, our Chief Financial Officer. Q2 was an important quarter for DiaMedica with progress across DM199 in early onset fetal growth restriction, preeclampsia and acute ischemic stroke. We advanced our pregnancy-related clinical strategy, continued preparations for our Phase II early onset preeclampsia study in Canada and the U.K. and made further progress towards reaching the planned Phase II/III ReMEDy2 interim analysis in acute ischemic stroke. There are four key updates I would like to highlight. First, with respect to the IST being conducted by Professor Cluver, enrollment has been completed in the first cohort of the Phase II early onset fetal growth restriction study. The cohort consists of six participants treated at the 5 microgram per kg dose level. This is important as it expands the clinical use of DM199 into a second serious women's health disorder for which there are no approved therapies. We plan to host a key opinion leader event in September with Professor Cathy Cluver, the study's principal investigator and other experts to discuss the potential of DM199 in fetal growth restriction and share top line results for the completed first cohort open-label Phase II trial. Second, the extension cohort from the Part 1a of the IST has been completed. This was the initial dose escalation cohort treating women with late-stage preeclampsia. The combined results from the dose escalation …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Dietrich John Pauls | President, Chief Executive Officer & Director | USD 1,074,950 | Male | 1971 | Active |
Julie Krop | Chief Medical Officer | USD 675,668 | — | 1966 | Active |
Scott Kellen | Chief Financial Officer & Corporate Secretary | USD 609,870 | Male | 1965 | Active |
Ambarish Shah | Chief Technology Officer | — | — | — | Active |
Dominic R. Cundari | Chief Commercial Officer | — | Male | 1951 | Active |
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York. Details Citi Biopharma Back to School Summit September 9-10, 2026 Cantor Global Healthcare Conference September 9-11, 2026 Fireside Chat with Rick Pauls (CEO).
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
